H2020Индивидуална стипендия2016–2018

PHOTO ORGANO-GOLD · Driving asymmetric photoreactions by merging organo- and gold-catalysis

„Хоризонт 2020“ — Действия „Мария Склодовска-Кюри“

Период: 2016-05-06 → 2018-05-05
Финансиране от ЕС: 158 122 €
Участници: 1
Схема: MSCA-IF-EF-ST

Линиите свързват координатора с партньорите.

Накратко на български

Нови химични реакции, комбиниращи органичен и златен катализатор, се разработват за създаване на специфични хирални молекули чрез светлина. Те помагат за по-ефективното откриване на нови лекарствени структури при щадящи условия.

Този кратък обзор е генериран от изкуствен интелект

Кратко обяснение, генерирано от езиков модел по текста на CORDIS. Оригиналът е по-долу.

Резултати накратко

Driving asymmetric photoreactions by merging organo- and gold-catalysis

We are in a changing era for drug discovery:1 the growing perception is that basic, fundamental chemical research will play a greater role in pharmaceutical development. In this context, one current challenge is to develop a new kind of chemistry that yields a screening collection comprising optimal chiral molecules that increase the probability of success in identifying drug-candidate structures in a mild and efficient way,2 to promote the sustainability of the society. On the other hand, the chemistry community recognized how visible light-mediated photoreactions can open a new dimension for organic synthesis. The past decade have witnessed a remarkable prosperity in this area.3 In view of these, under the generous support of MSCA-IF (Project ID: 702405) from European Commission, Dr. Zhong-Yan Cao has conducted two-year postdoc research under the supervision of Prof. Dr. Paolo Melchiorre in the Institute of Chemical Research of Catalonia (ICIQ), attempting to challenge the above issue by developing conceptually new catalytic asymmetric photoreactions. Specifically, different from commonly used strategy for driving photoreactions with external photoredox catalysts4 to generate the reactive species, the photochemical activity of electron donor-acceptor (EDA) complexes provides an alternative way to generate radicals under mild conditions and without the need of external photoredox catalysts.5 Nevertheless, reported methods classically relied on the formation of intermolecular EDA complexes, generated upon aggregation of two suitable substrates/intermediate (see picture 1 for details). How to extend the strategy in an intramolecular way along with exploiting the synthetic application of the strategy was still elusive. As a proof-of-concept, the current project offers the first demonstration that photon-absorbing intramolecular EDA complex is potential for synthetic applications. J. W. Scannell, A. Blanckley and B. Warrington, Nature Reviews Drug Discovery 2012, 11, 191. 2 T. E. Nielsen and S. L. Schreiber, Angew. Chem. Int. Ed. 2008, 47, 48. 3 C. K. Prier, D. A. Rankic and D. W. C. MacMillan, Chem. Rev. 2013, 113, 5322 4 M. H. Shaw, J. Twilton and D. W. C. MacMillan, J. Org. Chem. 2016, 81, 6898. 5 C. G. S. Lima, T. Lima, M. Duarte, I. D. Jurberg and M. W. Paixão, ACS Catal. 2016, 6, 1389.

Текст от CORDIS, на английски · Данни: CORDIS, © Европейски съюз

Цел на проекта

We are in a changing era for drug discovery: the growing perception is that basic chemical research will play a greater role in pharmaceutical development. One current challenge is to develop a new kind of chemistry that yields a screening collection comprising optimal chiral molecules that increase the probability of success in identifying drug-candidate structures. Also, the chemistry community has recently recognized how visible light-mediated photoreactions can open new avenues in modern organic synthesis and the past seven years have witnessed its remarkable prosperity. Therefore, developing photo-facilitated asymmetric reactions focusing on rapidly generating privileged chiral natural-like compounds for drug discovery are highly desirable. The proposed research aims to combine the fellow’s experience in gold catalysis and the host’s experience in photo-triggered organocatalysis (two powerful fields of molecule activation, which have to date remained unrelated) to develop otherwise unachievable catalytic asymmetric photoreactions. Specifically, we will focus on using readily available, unactivated aryl/alkyl chloride or bromide, which cannot be easily activated by the commonly used Rh- or Ir-based photoredox catalysts. The resulting strategies will be used as an ideal platform for assembling libraries comprising enantiopure chiral small molecules bearing α,α-disubstituted α-amino acid & 3,3-disubstituted oxindole frameworks, which, along with biological screening carried out in collaboration with a world-wide recognized pharma-company (Lundbeck A/S, Copenhagen, DK), will increase the probability of success in identifying drug-candidate structures. The multi-cultural nature of this project will greatly contribute to broaden the fellow competencies and will place him in an excellent position for the next career move

Оригинален текст от CORDIS (на английски).

Участници

FUNDACIO INSTITUT CATALA D'INVESTIGACIO QUIMICA · TARRAGONAКоординаторИспания